TG治疗 TGTX 深 沪
已收盘 02-06 16:00:00 美东时间
28.86
+1.100
+3.96%
华盛通- 最 高28.95
- 今 开28.25
- 成交量 162.22万股
- 最 低 27.83
- 昨 收 27.76
- 总市值 45.82亿
- 52周最高 46.48
- 市盈率 静 197.94
- 换手率 1.02%
- 52周最低 25.28
- 委 比 -86.17%
- 总股本 1.59亿
- 历史最高 56.74
- 量 比 0.87
- 振 幅 4.03%
- 历史最低 0.9563
- 每 手 1
- 风险率 3.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
TG Therapeutics To Present Data On BRIUMVI At Americas Committee For Treatment And Research In Multiple Sclerosis Annual Forum From Feb. 5 To 6 In San Diego
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in
01-27 20:38
美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $39
Goldman Sachs analyst Corinne Johnson maintains TG Therapeutics (NASDAQ:TGTX) with a Neutral and raises the price target from $37 to $39.
01-15 18:04
Bank of America, Citigroup And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading lower this morning on Wednesday, some of the st...
01-14 16:57
TG Therapeutics Stock Climbs After The Bell: Here's Why
TG Therapeutics releases its preliminary Q4 revenue estimates and provides an optimistic outlook for 2026.
01-14 06:05
TG Therapeutics Expects FY25 Total Global Revenue Of ~$616M, Anticipates FY26 Total Global Revenue Range $875M - $900M
TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics), today announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2025 (unaudited), as
01-14 05:27
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
TG Therapeutics announced that CEO Michael Weiss will present at the 44th J.P. Morgan Healthcare Conference on January 13, 2026, at 1:30 PM PST. The presentation will be available live and on replay via the company's website. TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, with FDA-approved BRIUMVI® for multiple sclerosis treatment.
01-07 12:30
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
TG Therapeutics' CEO, Michael S. Weiss, will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, with a fireside chat on December 2 at 12:30 PM ET. A live webcast will be available on the company's website. TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, including approved therapies like BRIUMVI® for multiple sclerosis. More information is available on their we...
2025-11-28 12:30
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
TG Therapeutics ranked 27th on the 2025 Deloitte Technology Fast 500 list, highlighting its rapid growth driven by BRIUMVI® revenues, approved to treat multiple sclerosis in 2022. CEO Michael S. Weiss emphasized the company's commitment to innovation and improving care for autoimmune diseases.
2025-11-19 13:30
